Cargando…
NT-pro BNP in AECOPD-PH: old biomarker, new insights-based on a large retrospective case-controlled study
BACKGROUND: Pulmonary hypertension (PH) is one of the common complications in chronic obstructive pulmonary disease (COPD). The study aimed to evaluate the predicting ability of N-terminal pro brain natriuretic peptide (NT-pro BNP) in patients with AECOPD-PH and its relationship with the severity of...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711159/ https://www.ncbi.nlm.nih.gov/pubmed/34961527 http://dx.doi.org/10.1186/s12931-021-01917-3 |
_version_ | 1784623316506509312 |
---|---|
author | Tian, Fengming Song, Wen Wang, Liang Zeng, Qiang Zhao, Zhenyu Feng, Ning Fan, Jiahui Wang, Yue Wang, Jing Ma, Xiumin |
author_facet | Tian, Fengming Song, Wen Wang, Liang Zeng, Qiang Zhao, Zhenyu Feng, Ning Fan, Jiahui Wang, Yue Wang, Jing Ma, Xiumin |
author_sort | Tian, Fengming |
collection | PubMed |
description | BACKGROUND: Pulmonary hypertension (PH) is one of the common complications in chronic obstructive pulmonary disease (COPD). The study aimed to evaluate the predicting ability of N-terminal pro brain natriuretic peptide (NT-pro BNP) in patients with AECOPD-PH and its relationship with the severity of PH. METHODS: A large retrospective case-controlled study (n = 1072) was performed in the First Affiliated Hospital of Xinjiang Medical University from January 2018 to December 2020, and patients were divided into stable COPD (n = 178), AECOPD (n = 688) and AECOPD-PH group (n = 206). Different statistical models were used to screen for reliable and stable biomarkers. RESULTS: In unadjusted analysis and PSM (model 1, 2, 3), red cell distribution width (RDW), total bilirubin (TBIL), and NT-pro BNP were higher in patients with AECOPD-PH than those in AECOPD group. Logistic regression analysis showed, when the range of NT-proBNP was 271–1165 pg/mL (OR: 0.293; 95%CI: 0.184–0.467; P < 0.001) and NT-proBNP > 1165 pg/mL (OR: 0.559; 95%CI: 0.338–0.926; P = 0.024), the morbidity risk of PH in AECOPD patients was increased, so did TBIL. In receiver operating characteristic (ROC) curves, at the cut-off value of NT-proBNP was 175.14 pg/mL, AUC was 0.651 (P < 0.001), which was better than TBIL (AUC: 0.590, P < 0.001). As for the results of rank correlation analysis, NT-proBNP had a weak correlation with severity of PH with AECOPD (r(s) = 0.299, P = 0.001) and its relative relevance with other biomarkers (RDW was 0.359 and TBIL was 0.238, P < 0.001). CONCLUSIONS: Our findings suggest that NT-proBNP has a diagnostic efficacy in AECOPD-PH and NT-proBNP has a weak correlation with severity of PH with AECOPD. |
format | Online Article Text |
id | pubmed-8711159 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-87111592022-01-05 NT-pro BNP in AECOPD-PH: old biomarker, new insights-based on a large retrospective case-controlled study Tian, Fengming Song, Wen Wang, Liang Zeng, Qiang Zhao, Zhenyu Feng, Ning Fan, Jiahui Wang, Yue Wang, Jing Ma, Xiumin Respir Res Research BACKGROUND: Pulmonary hypertension (PH) is one of the common complications in chronic obstructive pulmonary disease (COPD). The study aimed to evaluate the predicting ability of N-terminal pro brain natriuretic peptide (NT-pro BNP) in patients with AECOPD-PH and its relationship with the severity of PH. METHODS: A large retrospective case-controlled study (n = 1072) was performed in the First Affiliated Hospital of Xinjiang Medical University from January 2018 to December 2020, and patients were divided into stable COPD (n = 178), AECOPD (n = 688) and AECOPD-PH group (n = 206). Different statistical models were used to screen for reliable and stable biomarkers. RESULTS: In unadjusted analysis and PSM (model 1, 2, 3), red cell distribution width (RDW), total bilirubin (TBIL), and NT-pro BNP were higher in patients with AECOPD-PH than those in AECOPD group. Logistic regression analysis showed, when the range of NT-proBNP was 271–1165 pg/mL (OR: 0.293; 95%CI: 0.184–0.467; P < 0.001) and NT-proBNP > 1165 pg/mL (OR: 0.559; 95%CI: 0.338–0.926; P = 0.024), the morbidity risk of PH in AECOPD patients was increased, so did TBIL. In receiver operating characteristic (ROC) curves, at the cut-off value of NT-proBNP was 175.14 pg/mL, AUC was 0.651 (P < 0.001), which was better than TBIL (AUC: 0.590, P < 0.001). As for the results of rank correlation analysis, NT-proBNP had a weak correlation with severity of PH with AECOPD (r(s) = 0.299, P = 0.001) and its relative relevance with other biomarkers (RDW was 0.359 and TBIL was 0.238, P < 0.001). CONCLUSIONS: Our findings suggest that NT-proBNP has a diagnostic efficacy in AECOPD-PH and NT-proBNP has a weak correlation with severity of PH with AECOPD. BioMed Central 2021-12-27 2021 /pmc/articles/PMC8711159/ /pubmed/34961527 http://dx.doi.org/10.1186/s12931-021-01917-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Tian, Fengming Song, Wen Wang, Liang Zeng, Qiang Zhao, Zhenyu Feng, Ning Fan, Jiahui Wang, Yue Wang, Jing Ma, Xiumin NT-pro BNP in AECOPD-PH: old biomarker, new insights-based on a large retrospective case-controlled study |
title | NT-pro BNP in AECOPD-PH: old biomarker, new insights-based on a large retrospective case-controlled study |
title_full | NT-pro BNP in AECOPD-PH: old biomarker, new insights-based on a large retrospective case-controlled study |
title_fullStr | NT-pro BNP in AECOPD-PH: old biomarker, new insights-based on a large retrospective case-controlled study |
title_full_unstemmed | NT-pro BNP in AECOPD-PH: old biomarker, new insights-based on a large retrospective case-controlled study |
title_short | NT-pro BNP in AECOPD-PH: old biomarker, new insights-based on a large retrospective case-controlled study |
title_sort | nt-pro bnp in aecopd-ph: old biomarker, new insights-based on a large retrospective case-controlled study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711159/ https://www.ncbi.nlm.nih.gov/pubmed/34961527 http://dx.doi.org/10.1186/s12931-021-01917-3 |
work_keys_str_mv | AT tianfengming ntprobnpinaecopdpholdbiomarkernewinsightsbasedonalargeretrospectivecasecontrolledstudy AT songwen ntprobnpinaecopdpholdbiomarkernewinsightsbasedonalargeretrospectivecasecontrolledstudy AT wangliang ntprobnpinaecopdpholdbiomarkernewinsightsbasedonalargeretrospectivecasecontrolledstudy AT zengqiang ntprobnpinaecopdpholdbiomarkernewinsightsbasedonalargeretrospectivecasecontrolledstudy AT zhaozhenyu ntprobnpinaecopdpholdbiomarkernewinsightsbasedonalargeretrospectivecasecontrolledstudy AT fengning ntprobnpinaecopdpholdbiomarkernewinsightsbasedonalargeretrospectivecasecontrolledstudy AT fanjiahui ntprobnpinaecopdpholdbiomarkernewinsightsbasedonalargeretrospectivecasecontrolledstudy AT wangyue ntprobnpinaecopdpholdbiomarkernewinsightsbasedonalargeretrospectivecasecontrolledstudy AT wangjing ntprobnpinaecopdpholdbiomarkernewinsightsbasedonalargeretrospectivecasecontrolledstudy AT maxiumin ntprobnpinaecopdpholdbiomarkernewinsightsbasedonalargeretrospectivecasecontrolledstudy |